| abstract |
Methods are provided for treating PI3K6 related disorders, such as lymphomas or leukemias, using compounds of Formula I: or pharmaceutically acceptable salts thereof. Also provided are uses of a compound of Fommla (IV): or a pharmaceutically acceptable salt thereof, for treatment of myelofibrosis, or other disorders, such as idiopathic thrombocytopenic purpura (ITP), autoimmune hemolytic anemia, Behcets disease, Cogan's syndrome, giant cell arteritis, etc. |